DPP4 and fatty liver disease: Gemigliptin, a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, was able to relieve hepatic steatosis and insulin resistance by suppressing LECT2 expressions involved in increased AMPK phosphorylations in HFD‐fed mice.31